These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 36678822)

  • 41. Dose-dependent anti-inflammatory effect of inhaled mometasone furoate/formoterol in subjects with asthma.
    Nolte H; Pavord I; Backer V; Spector S; Shekar T; Gates D; Nair P; Hargreave F
    Respir Med; 2013 May; 107(5):656-64. PubMed ID: 23490226
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dose-ranging study of a new steroid for asthma: mometasone furoate dry powder inhaler.
    Bernstein DI; Berkowitz RB; Chervinsky P; Dvorin DJ; Finn AF; Gross GN; Karetzky M; Kemp JP; Laforce C; Lumry W; Mendelson LM; Nelson H; Pearlman D; Rachelefsky G; Ratner P; Repsher L; Segal AT; Selner JC; Settipane GA; Wanderer A; Cuss FM; Nolop KB; Harrison JE
    Respir Med; 1999 Sep; 93(9):603-12. PubMed ID: 10542973
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy and safety of two dry-powder inhalers for the administration of mometasone furoate in asthma patients.
    Pereira CA; Vianna FF; Cukier A; Stelmach R; Oliveira JC; Carvalho EV; Gomes EP; Mayo SV; Chibante AM; Domingues CP
    J Bras Pneumol; 2010; 36(4):410-6. PubMed ID: 20835586
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of mometasone furoate administered via a dry powder inhaler once daily in the evening on nocturnal lung function and sleep parameters in patients with moderate persistent asthma: a randomized, double-blind, placebo-controlled pilot study.
    Krouse JH; Krouse HJ; Janisse JJ
    Clin Drug Investig; 2009; 29(1):51-8. PubMed ID: 19067474
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Population Pharmacokinetic Analysis of Indacaterol/Glycopyrronium/Mometasone Furoate After Administration of Combination Therapies Using the Breezhaler
    Bartels C; Jain M; Yu J; Tillmann HC; Vaidya S
    Eur J Drug Metab Pharmacokinet; 2021 Jul; 46(4):487-504. PubMed ID: 34024035
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Indacaterol acetate/mometasone furoate provides sustained improvements in lung function compared with salmeterol xinafoate/fluticasone propionate in patients with moderate-to-very-severe COPD: results from a Phase II randomized, double-blind 12-week study.
    Beeh KM; Kirsten AM; Tanase AM; Richard A; Cao W; Hederer B; Beier J; Kornmann O; van Zyl-Smit RN
    Int J Chron Obstruct Pulmon Dis; 2018; 13():3923-3936. PubMed ID: 30584293
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy of one time per day, single-inhaler indacaterol/glycopyrronium/mometasone in patients with inadequately controlled asthma: post hoc analysis of IRIDIUM study in Asian population.
    Sagara H; Barbier N; Ishii T; Yoshisue H; Nikolaev I; Hosoe M; Gon Y
    BMJ Open Respir Res; 2021 Mar; 8(1):. PubMed ID: 33737310
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Inhaled mometasone furoate: a review of its use in adults and adolescents with persistent asthma.
    Sharpe M; Jarvis B
    Drugs; 2001; 61(9):1325-50. PubMed ID: 11511026
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of a Thermosensitive In Situ Gel Containing Mometasone Furoate on a Rat Allergic Rhinitis Model.
    Altuntaş E; Yener G; Doğan R; Aksoy F; Şerif Aydın M; Karataş E
    Am J Rhinol Allergy; 2018 May; 32(3):132-138. PubMed ID: 29644886
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trials.
    Tashkin DP; Doherty DE; Kerwin E; Matiz-Bueno CE; Knorr B; Shekar T; Gates D; Staudinger H
    Int J Chron Obstruct Pulmon Dis; 2012; 7():73-86. PubMed ID: 22334770
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy and safety of a fixed-dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52-week Phase III trial.
    Tashkin DP; Doherty DE; Kerwin E; Matiz-Bueno CE; Knorr B; Shekar T; Banerjee S; Staudinger H
    Int J Chron Obstruct Pulmon Dis; 2012; 7():43-55. PubMed ID: 22334768
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ocular symptom reduction in patients with seasonal allergic rhinitis treated with the intranasal corticosteroid mometasone furoate.
    Bielory L
    Ann Allergy Asthma Immunol; 2008 Mar; 100(3):272-9. PubMed ID: 18434976
    [TBL] [Abstract][Full Text] [Related]  

  • 53. DIBI, a polymeric hydroxypyridinone iron chelator, reduces ocular inflammation in local and systemic endotoxin-induced uveitis.
    Arora N; Caldwell A; Wafa K; Szczesniak A; Caldwell M; Al-Banna N; Sharawy N; Islam S; Zhou J; Holbein BE; Kelly MEM; Lehmann C
    Clin Hemorheol Microcirc; 2018; 69(1-2):153-164. PubMed ID: 29630535
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The anti-inflammatory effect of minocycline on endotoxin-induced uveitis and retinal inflammation in rats.
    Yuan Z; Chen X; Yang W; Lou B; Ye N; Liu Y
    Mol Vis; 2019; 25():359-372. PubMed ID: 31354229
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate administered as an inhaled fixed-dose combination in Japanese and Caucasian healthy subjects.
    Inoue S; Vaidya S; Tillmann HC; Sakita Y; Machineni S; Heudi O; Furihata K
    BMC Pulm Med; 2021 Jan; 21(1):18. PubMed ID: 33413291
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate following once-daily inhalation as a combination in healthy subjects.
    Vaidya S; Jauernig J; Ethell B; Abdallah N; Machineni S; Drollmann A; Heudi O; Last S; Hahn M; Radhakrishnan R; Ignatenko S; Tillmann HC
    Pulm Pharmacol Ther; 2020 Oct; 64():101964. PubMed ID: 33035700
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Once-daily mometasone furoate dry powder inhaler in the treatment of patients with persistent asthma.
    Nayak AS; Banov C; Corren J; Feinstein BK; Floreani A; Friedman BF; Goldsobel A; Gottschlich GM; Hannaway PJ; Lampl KL; Lapidus RJ; Lawrence M; Lumry W; Munk Z; Pearlman D; Scardella AT; Schenkel EJ; Segal AT; Segall N; Silverman B; Shneyer L; Nolop KB; Harrison JE
    Ann Allergy Asthma Immunol; 2000 Apr; 84(4):417-24. PubMed ID: 10795650
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Indacaterol, glycopyrronium, and mometasone: Pharmacological interaction and anti-inflammatory profile in hyperresponsive airways.
    Rogliani P; Ritondo BL; Facciolo F; Matera MG; Nikolaev I; Calzetta L
    Pharmacol Res; 2021 Oct; 172():105801. PubMed ID: 34363950
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of once-daily indacaterol maleate/mometasone furoate on exacerbation risk in adolescent and adult asthma: a double-blind randomised controlled trial.
    Beasley RW; Donohue JF; Mehta R; Nelson HS; Clay M; Moton A; Kim HJ; Hederer BM
    BMJ Open; 2015 Feb; 5(2):e006131. PubMed ID: 25649209
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Use of mometasone furoate administered via a dry powder inhaler in the treatment of asthma.
    Zeidler M; Corren J; Tashkin DP
    Curr Med Res Opin; 2010 Jun; 26(6):1295-305. PubMed ID: 20370376
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.